Merus

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The FDA bestows a Fast Track status to Merus' (MRUS) lead pipeline candidate, Zenocutuzumab, for treating metastatic solid tumors harboring NRG1 gene fusions. Shares rise.

Merus (MRUS) Stock Up on FDA's Fast Track Tag for Zenocutuzumab

NRG1 fusions are rare mutations in many types of solid tumors, including non-small cell lung cancer and pancreatic cancer NRG1 fusions are rare mutations in many types of solid tumors, including non-small cell lung cancer and pancreatic cancer

Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers

UTRECHT, The Netherlands and STAMFORD, Conn., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multi-specific antibodies (Biclonics® and TriclonicsTM), and Sem a 4, a patient-centered health intelligence company, today announced they have entered into a strategic agreement to utilize Sema4's advanced genomic testing to identify patients with tumors harboring neuregulin 1 gene (NRG1) fusions who may be eligible for investigational treatment with the bispecific antibody Zenocutuzumab (“Zeno”) in the Phase 1/2 eNRGy trial sponsored by Merus.

Merus and Sema4 Enter Into an Agreement to Support Merus' Phase 1/2 Clinical Trial of Zenocutuzumab

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Merus N.V.  (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that Bill Lundberg, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 14:40 p.m. GMT/9:40 a.m. ET.

Merus to Present at the Jefferies Virtual London Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that preclinical data from its MCLA-145 program will be presented at the Society for Immunotherapy of Cancer (SITC) annual meeting being held virtually on November 1015, 2020.

Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- myTomorrows, a global health technology company, and Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the expansion of their ongoing collaboration to raise awareness of screening opportunities for and recruitment of patients with neuregulin 1 (NRG1) fusion cancers.

Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors

Merus (MRUS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Merus (MRUS) Looks Good: Stock Adds 7% in Session

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Aug.  07, 2020  (GLOBE NEWSWIRE) --  Merus N.V.  (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that Bill Lundberg, M.D., President and Chief Executive Officer, will present a company overview at the 2020 Wedbush PacGrow Healthcare Conference on Wednesday, August 12, 2020 at 10:20 a.m. ET.

Merus to Present at the 2020 Wedbush PacGrow Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July  27, 2020  (GLOBE NEWSWIRE) --  Merus N.V.  (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Zenocutuzumab (Zeno) for the treatment of patients with pancreatic cancer.  

Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer

Dr. Joe brings seasoned research and development leadership and deep expertise in the clinical development of immuno-oncology, antibody, and targeted therapies for cancer Dr. Joe brings seasoned research and development leadership and deep expertise in the clinical development of immuno-oncology, antibody, and targeted therapies for cancer

Merus Appoints Andrew Joe, M.D., as Chief Medical Officer

Caris to provide DNA and RNA molecular testing to support  patient identification and enrollment for Merus’ Zenocutuzumab Phase 1/2 eNRGy trial

Merus and Caris Life Sciences Announce Collaboration to Detect NRG1 Fusions in Cancer Patients

– MCLA-128, zenocutuzumab, independent epidemiology analysis reaffirms significant clinical and commercial potential in NRG1 fusion cancers –– MCLA-117 demonstrates limited clinical activity in Phase 1 trial –– Extensive panel of novel CD3 bispecific antibodies provides important insights and avenues to maximize T‑cell engager biology –

Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates

Merus NV (MRUS) delivered earnings and revenue surprises of -25.93% and -21.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Merus NV (MRUS) Reports Q1 Loss, Misses Revenue Estimates

Merus: Catalyst Filled 2020 For Biclonics Platform, Concerns Remain

— Bill Lundberg, M.D., nominated for appointment as Chief Executive Officer —— Ton Logtenberg, Ph.D., to step down after 16 years of leadership —— Transition to occur December 31, 2019 —

Merus Announces Chief Executive Officer Transition

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov.  04, 2019  (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the launch of a proposed underwritten public offering of up to $60.0 million of its common shares. All of the common shares are being offered by Merus N.V. In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional $9.0 million of its common shares at the public offering price, on the same terms and conditions. The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares

Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancreatic, one non-small cell lung cancer) presented by investigators at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions

MacroGenics

Seagen

Zymeworks Inc

With Breast Cancer Awareness Month drawing to a close and the San Antonio Breast Cancer Symposium on the horizon, stay alert for breaking news from companies developing new treatments.

4 Stocks Battling Breast Cancer

Company to host investor call on Monday, October 28th at 8:00AM ET Company to host investor call on Monday, October 28th at 8:00AM ET

Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Merus N.V. (MRUS) delivered earnings and revenue surprises of -5.56% and -27.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates

UTRECHT, The Netherlands, Aug.  19, 2019  (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced financial results for the second quarter ended June 30, 2019 and provided a business update.

Merus Announces Financial Results for the Second Quarter 2019 and Provides Business Update

Merus is looking like an interesting pick from a technical perspective.

Moving Average Crossover Alert: Merus

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Merus N.V. (MRUS) Report Negative Q2 Earnings?

As of late, it has definitely been a great time to be an investor in Merus N.V. (MRUS).

Merus N.V. (MRUS) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Merus.

News for Merus Stock (MRUS)